Sokoloff RL, Norton KC, Gasior CL et al (2000) A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 43:150–157
Ross JS, Sheehan CE, Fisher HA et al (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362
Perner S, Hofer MD, Kim R et al (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701
Bednarova S, Lindenberg ML, Vinsensia M et al (2017) Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. Transl Androl Urol 6:413–423
Eiber M, Fendler WP, Rowe SP et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58:67S-76S
Afshar-Oromieh A, da Cunha ML, Wagner J et al (2021) Performance of 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging 48:2925–2934
Abghari-Gerst M, Armstrong WR, Nguyen K et al (2022) A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. J Nucl Med 63:567–572
Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a 68Gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
Eder M, Neels O, Muller M et al (2014) Novel preclinical and radiopharmaceutical aspects of 68Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779–796
Giesel FL, Hadaschik B, Cardinale J et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688
Giesel FL, Knorr K, Spohn F et al (2019) Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60:362–368
Wondergem M, van der Zant FM, Knol RJJ et al (2017) 18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes: detection rate, image quality, activity kinetics, and biodistribution. J Nucl Med 58:1797–1804
Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340–351
D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
Arnfield EG, Thomas PA, Roberts MJ et al (2021) Clinical insignificance of [18F]PSA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging 48:4495–4507
Rahbar K, Afshar-Oromieh A, Seifert R et al (2018) Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45:2055–2061
AhmadiBidakhvidi N, Laenen A, Jentjens S et al (2021) Parameters predicting 18F-PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Res 11:41
Sachpekidis C, Baumer P, Kopka K et al (2018) 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 45:904–912
Afshar-Oromieh A, Vollnberg B, Alberts I et al (2019) Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging 46:2289–2297
Zhou J, Gou Z, Wu R et al (2019) Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol 48:1915–1924
Hernandez D, Salas D, Gimenez D et al (2015) Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy. Radiat Oncol 10:262
Liauw SL, Pitroda SP, Eggener SE et al (2013) Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys 85:378–384
Stoll M, Stoiber EM, Grimm S et al (2016) Comparison of safety margin generation concepts in image guided radiotherapy to account for daily head and neck pose variations. PLoS ONE 11:e0168916
Peters N, Wohlfahrt P, Hofmann C et al (2022) Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction. Radiother Oncol 166:71–78
Trofimov A, Nguyen PL, Coen JJ et al (2007) Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 69:444–453
Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase iii trial. J Clin Oncol 39:787–796
Salembier C, Villeirs G, De Bari B et al (2018) ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 127:49–61
留言 (0)